By Ken Garber | Nature Reviews Drug Discovery
Nature Reviews Drug Discovery conducted a deep dive into menin inhibitors, a promising emerging drug class for acute leukemias – also referred to as leukaemia in some dialects.
This close look highlights the history of menin inhibitors, including the early research that took place at the University of Michigan, leading to the eventual clinical development of Kura’s ziftomenib for patients with acute myeloid leukemia (AML). The article also touches on the genetic subtypes of AML, provides an overview of the menin inhibitors in development, and highlights the potential for menin inhibitors to provide a new hope to patients.
Read more including commentary from Kura’s President & CEO Troy Wilson, along with other industry and advocacy leaders.
